Immunotech Biopharm's (HKG:6978) CAR-T-19 obtained breakthrough therapy designation for treating patients aged 25 and below with relapsed/refractory B-cell acute lymphoblastic leukemia.
The designation, granted by the Center for Drug Evaluation of China's National Medical Products Administration, will expedite the clinical development of CAR-T-19.
The designation was awarded based on the "solid" clinical efficacy and safety data of CAR-T-19, Immunotech said in a Wednesday filing with the Hong Kong Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments